中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2015年
5期
435-437
,共3页
奈达铂%多西他赛%放射疗法%宫颈癌
奈達鉑%多西他賽%放射療法%宮頸癌
내체박%다서타새%방사요법%궁경암
Nedaplati%Docetaxel%Radiotherapy%Cervical cancer
目的 观察奈达铂、多西他赛联合放疗治疗局部晚期宫颈癌的临床效果.方法 选取2013年6月至2014年7月唐山市妇幼保健院收治的经病理确诊的宫颈癌患者99例,将其随机分为对照组和观察组.对照组45例,采用单纯放疗治疗.观察组54例,在对照组基础上采用奈达铂联合多西他赛同期化疗.结果 观察组总有效率(90.74%)明显高于对照组(71.11%),两组比较差异有统计学意义(x2 =6.358,P=0.017).两组均有较明显的消化道反应、肾功能损伤及骨髓抑制,但均能耐受.且两组不良反应比较差异无统计学意义(P>0.05).结论 奈达铂、多西他赛联合同期放疗治疗局部晚期宫颈癌效果较好,且不会增加不良反应发生率,可以作为有效的临床方案.
目的 觀察奈達鉑、多西他賽聯閤放療治療跼部晚期宮頸癌的臨床效果.方法 選取2013年6月至2014年7月唐山市婦幼保健院收治的經病理確診的宮頸癌患者99例,將其隨機分為對照組和觀察組.對照組45例,採用單純放療治療.觀察組54例,在對照組基礎上採用奈達鉑聯閤多西他賽同期化療.結果 觀察組總有效率(90.74%)明顯高于對照組(71.11%),兩組比較差異有統計學意義(x2 =6.358,P=0.017).兩組均有較明顯的消化道反應、腎功能損傷及骨髓抑製,但均能耐受.且兩組不良反應比較差異無統計學意義(P>0.05).結論 奈達鉑、多西他賽聯閤同期放療治療跼部晚期宮頸癌效果較好,且不會增加不良反應髮生率,可以作為有效的臨床方案.
목적 관찰내체박、다서타새연합방료치료국부만기궁경암적림상효과.방법 선취2013년6월지2014년7월당산시부유보건원수치적경병리학진적궁경암환자99례,장기수궤분위대조조화관찰조.대조조45례,채용단순방료치료.관찰조54례,재대조조기출상채용내체박연합다서타새동기화료.결과 관찰조총유효솔(90.74%)명현고우대조조(71.11%),량조비교차이유통계학의의(x2 =6.358,P=0.017).량조균유교명현적소화도반응、신공능손상급골수억제,단균능내수.차량조불량반응비교차이무통계학의의(P>0.05).결론 내체박、다서타새연합동기방료치료국부만기궁경암효과교호,차불회증가불량반응발생솔,가이작위유효적림상방안.
Objective To investigate the efficacy of nedaplati docetaxel combined with radiotherapy on patients with locally advanced cervical cancer.Methods The clinical data of 99 cases with pathologically diagnosed advanced cervical cancer from Jun.2013 to jul.2014 in the Matemal and Child Health Care Hospital of Tangshan were recorded.The patients were randomly divided into the control group (45 cases only with radiotherapy) and the observation group(54 cases with nedaplati and docetaxel beside radiotherapy).Results The effective rate in observation group was 90.74%,higher than control group (71.11%,x2 =6.358,P =0.017).There were significant incidence of bone marrow suppression renal dysfunction and gastrointestinal both in two groups,but can endure.There was no significant difference in term of side effect in two groups (P >0.05).Conclusion The therapy of nedaplati and docetaxel combined with radiotherapy has better effect for patients with advanced cervical cancer and without significantly increasing side effect.